Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.
Hosted on MSN
Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown ...
CePA exerts a liver-targeted mTOR repressive function, alleviating MASH progression and fat accumulation in high-fat diet-fed mice. Metabolic dysfunction-associated steatohepatitis (MASH) is one of ...
Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses. Although the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results